Dupixent CTCL MDL 3180: What the Transfer Order Means for Patients
The federal Dupixent CTCL cases now have one home court.
On June 4, 2026, the Judicial Panel on Multidistrict Litigation sent the federal cases to the District of New Jersey and created MDL No. 3180. Judge Zahid N. Quraishi is handling the coordinated pretrial work.
That may sound like court housekeeping. For a patient or a spouse trying to figure out what happened, it is more than that. It means the early fight over records, company documents, expert testimony, and common legal issues will be handled together instead of in scattered courts around the country.
It does not mean there is a settlement. It does not mean a court has decided Dupixent caused CTCL. The MDL is a process, not a verdict.
What changed in June
The JPML transfer order says the litigation started with fifteen actions and seven possible tag-along actions across twelve federal districts. The defendants named in the order include Regeneron Pharmaceuticals, Sanofi-Aventis U.S. LLC, and Genzyme Corporation.
The order describes the basic claim in plain terms. Most plaintiffs say they used Dupixent, also called dupilumab, for atopic dermatitis and later received a diagnosis of cutaneous T-cell lymphoma, or CTCL. Other claims were brought by spouses or survivors of Dupixent users who were diagnosed with CTCL.
One detail in the order is worth slowing down for. The defendants asked the panel to keep the MDL limited to CTCL cases. The panel noted that the cases before it did not have plaintiffs claiming non-cutaneous T-cell lymphoma as the primary injury. So, for now, MDL 3180 is focused on CTCL allegations.
The panel also explained why New Jersey made sense. Sanofi's principal place of business is in that district. Regeneron is headquartered nearby in Tarrytown, New York, and the order says Regeneron has corporate offices in New Jersey. In other words, the court expects important witnesses and company records to be close to the transferee court.
Why these cases can be hard to sort out
CTCL can involve the skin. That is one reason these cases are not simple.
Some people who later receive a CTCL diagnosis first spend months, sometimes longer, being treated for a skin condition that looks like eczema or another chronic rash. A patient may have seen a dermatologist, tried creams, changed medications, taken photos, gone back when the rash did not behave the way anyone expected, and only later had a biopsy that changed the conversation.
That timeline matters. It is also easy to lose.
Patient portals close. Doctors move. Pharmacies do not keep quick online histories forever. Family members remember the worst appointment but not the date. None of that is unusual. It is just the reason we tell people to gather the records early if they are even thinking about a review.
Records to pull before they disappear
A Dupixent CTCL review usually starts with documents, not guesses. Helpful records may include:
- Dermatology notes from before Dupixent was prescribed
- The first Dupixent prescription date
- Pharmacy fill history, including gaps or stop dates
- Office notes explaining why Dupixent was started
- Photos or chart notes showing changes in the rash or plaques
- Biopsy reports and dermatopathology reports
- Oncology or hematology records after the CTCL diagnosis
- Records showing a delayed diagnosis, changed diagnosis, or second opinion
If a biopsy was done, ask where the slides or tissue blocks are stored. Families often do not know those materials exist until a lawyer or doctor asks for them later.
Dates are the spine of the review. When did the skin symptoms begin? When did Dupixent start? What changed during treatment? When did a doctor first suspect CTCL? When was it confirmed?
A clean timeline will not prove a case by itself. It can, however, keep the review grounded in facts instead of memory.
What not to read into the MDL
There are a few things families should not assume.
A CTCL diagnosis after Dupixent use does not automatically mean the drug caused the disease. The MDL does not set a dollar value for claims. It does not guarantee that every unfiled claim will qualify. It also does not replace medical advice from a treating dermatologist, oncologist, or hematologist.
What the MDL does is give the federal cases a structure. The New Jersey court can manage discovery, expert questions, and pretrial rulings in one place. Those rulings may shape individual cases later, but each person's medical history still has to stand on its own.
A sensible next step
If you used Dupixent and were later diagnosed with CTCL, start by saving the records. If the patient has died, a spouse or family member may need to collect records from several offices and labs.
Do not rely on a short portal summary if you can get the full chart. Ask for the complete dermatology file, the oncology file, biopsy and pathology records, and the pharmacy history.
Mass Tort America is following MDL 3180 in New Jersey. We review these cases carefully because the details are not interchangeable. The diagnosis, the timing, and the medical records all matter.
Informational and attorney advertising disclaimer
This article is general information and may be considered attorney advertising. It is not medical advice or legal advice for your specific situation. Reading this article or contacting Mass Tort America does not create an attorney-client relationship. No outcome, settlement, or recovery is guaranteed.
